Bright Peak Therapeutics logo

Bright Peak Therapeutics

Better Biologics Through Chemistry

56 employees · est. 2017 · Basel, Switzerland

VS
Synaffix logo

Synaffix

A Lonza Company

63 employees · est. 2014 · Oss, The Netherlands

Synaffix is the older company (2017 vs 2014).

Side-by-Side Comparison

Bright Peak Therapeutics Synaffix
Founded
2017 2014 older
Headquarters
Basel, Switzerland Oss, The Netherlands
Employees
56 63
Industry
Biotechnology, Health and Wellness, Life Sciences Biotechnology, Health Care, Health and Wellness
Funding Stage
Series C Acquired
Total Funding
$232.00M $100.00M
Funding Rounds
3 3
Services
Development of multifunctional precision immunotherapies through protein engineering and chemical synthesis ADC Platform Licensing, Bispecific Antibody Development, Targeted Therapy Development, Out-licensing Technology for Cancer Therapeutics
Target Customers
Patients with cancer and autoimmune diseases, pharmaceutical companies, research institutions Pharmaceutical Companies, Biotechnology Firms, Oncology Researchers, Strategic Partners in Therapeutics
Taxonomy
Immunotherapy, Biologics, Cytokines, Antibody Conjugation, Cancer Treatment, Autoimmune Disease Treatment, Therapeutic Antibodies, Drug Development, Innovation, Biotech Research, Cell-Specific Targeting, Efficacy Enhancement, Precision Medicine, ADC-like Conjugation Technology Antibody-Drug Conjugates, ADC Technology Platform, Licensed Partnerships, Biotech Innovation, Clinical-Stage Development, Enzymatic Glycan Modification, Metal-Free Click Chemistry, Site-Specific Conjugation, Cancer Therapeutics, Immune Cell Engagers, Targeted Gene Therapy, Bispecific Antibodies, Patent Portfolio, Phase 1 Clinical Trials, High Growth Market Segments
Website
brightpeaktx.com synaffix.com
Bright Peak Therapeutics logo

About Bright Peak Therapeutics

Bright Peak Therapeutics, founded in 2017 and headquartered in Switzerland, is revolutionizing biologics with its pioneering approach. The company's portfolio of first-in-class and best-in-class cytokines, aimed at treating cancer and autoimmune diseases, leverages proprietary technology platforms t...

Synaffix logo

About Synaffix

Synaffix, a Lonza Company, is a pioneering biotech firm founded in 2014 and headquartered in The Netherlands. It boasts a proprietary, clinical-stage technology platform focused on antibody-drug conjugates (ADCs), renowned for optimizing safety and efficacy. The platform's value is underscored by m...

Be first to know when either one moves

Funding rounds, hiring surges, leadership changes and stack switches at Bright Peak Therapeutics and Synaffix — tracked continuously, sent the day they land.

Watch both — free

Funding, hiring, leadership and stack changes at Bright Peak Therapeuti... and Synaffix — by email.

Frequently Asked Questions

Bright Peak Therapeutics — Better Biologics Through Chemistry. Synaffix — A Lonza Company. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Bright Peak Therapeutics has raised $232.00M while Synaffix has raised $100.00M.
Bright Peak Therapeutics and Synaffix operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Bright Peak Therapeutics with someone else

Start typing a company name or domain.

One analytics cookie (Google Analytics). Cookie Policy